Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

TuHURA Biosciences, Inc./NV (HURA)

$2.11 -1.86% NASDAQ: HURA · 15-min delayed
  • TAMPA, Florida
  • Public · NASDAQ: HURA
  • 22 employees
$125.1MMarket cap
$0Revenue · FY2025
-$30.1MNet income
22Employees
HURANASDAQ
2024IPO

About TuHURA Biosciences, Inc./NV

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$0
Net income
-$30.1M
Total assets
$27.4M
Market cap
$125.1M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$31.8M
Income tax
$1.6K
Net income
-$30.1M
EPS (basic)
$-0.63
EPS (diluted)
$-0.63

Balance sheet

Total assets
$27.4M
Current assets
$4.6M
Total liabilities
$6.4M
Current liabilities
$5.9M
Shareholders’ equity
$20.9M

Cash flow

Operating cash flow
-$27.6M
Investing cash flow
-$1.3M
Financing cash flow
$19.9M
Net cash flow
-$9.0M

Statements via Polygon.io (SEC filings)

NASDAQ: HURA
$2.11 -1.86%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.44 $3.25

52-week range

Market cap
$125.1M
EPS (diluted)
$-0.63
Shares outstanding
59.3M
Open
Day range
Prev close
Volume
IPO date
Oct 18, 2024

TuHURA Biosciences, Inc./NV (HURA) Stock Price

  • Reported a net loss of $30.1M in FY2025.
  • Trading 35% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review TuHURA Biosciences, Inc./NV.

Write a review
Newsroom

News about TuHURA Biosciences, Inc./NV

News & sentiment via Polygon.io

FAQ

TuHURA Biosciences, Inc./NV: frequently asked questions

Is TuHURA Biosciences, Inc./NV an American company?

TuHURA Biosciences, Inc./NV is a US-based company headquartered in Tampa, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is TuHURA Biosciences, Inc./NV headquartered?

TuHURA Biosciences, Inc./NV is headquartered in Tampa, Florida, United States.

Is TuHURA Biosciences, Inc./NV publicly traded?

Yes — TuHURA Biosciences, Inc./NV is a publicly traded company. Its stock trades under the ticker symbol HURA on the NASDAQ.

What does TuHURA Biosciences, Inc./NV do?

TuHURA Biosciences, Inc./NV is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →